179 related articles for article (PubMed ID: 22890768)
21. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
Verweij PE; Te Dorsthorst DT; Rijs AJ; De Vries-Hospers HG; Meis JF
J Clin Microbiol; 2002 Jul; 40(7):2648-50. PubMed ID: 12089298
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
MacCallum DM; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
[TBL] [Abstract][Full Text] [Related]
23. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
25. Azole preexposure affects the Aspergillus fumigatus population in patients.
Alanio A; Cabaret O; Sitterlé E; Costa JM; Brisse S; Cordonnier C; Bretagne S
Antimicrob Agents Chemother; 2012 Sep; 56(9):4948-50. PubMed ID: 22710122
[TBL] [Abstract][Full Text] [Related]
26. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
27. Inflammation is associated with voriconazole trough concentrations.
van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
[TBL] [Abstract][Full Text] [Related]
28. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
[TBL] [Abstract][Full Text] [Related]
29. Voriconazole. UK 109496.
Drugs R D; 1999 Feb; 1(2):187-8. PubMed ID: 10566023
[No Abstract] [Full Text] [Related]
30. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
31. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
32. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.
Escribano P; Recio S; Peláez T; Bouza E; Guinea J
Antimicrob Agents Chemother; 2011 May; 55(5):2460-2. PubMed ID: 21321141
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.
Salas V; Pastor FJ; Calvo E; Sutton DA; Fothergill AW; Guarro J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1404-8. PubMed ID: 23295918
[TBL] [Abstract][Full Text] [Related]
34. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
35. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.
Henry ME; Bolo NR; Zuo CS; Villafuerte RA; Cayetano K; Glue P; Damle BD; Andrews E; Lauriat TL; Rana NS; Churchill JH; Renshaw PF
Antimicrob Agents Chemother; 2013 Nov; 57(11):5271-6. PubMed ID: 23939898
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of voriconazole in adults.
Hope WW
Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
[TBL] [Abstract][Full Text] [Related]
37. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.
Dannaoui E; Garcia-Hermoso D; Naccache JM; Meneau I; Sanglard D; Bouges-Michel C; Valeyre D; Lortholary O
J Med Microbiol; 2006 Oct; 55(Pt 10):1457-1459. PubMed ID: 17005798
[TBL] [Abstract][Full Text] [Related]
38. [Voriconazole-medicalneeds, evidence, potential for the future].
Shirasawa H; Nagino K
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):223-8. PubMed ID: 16282963
[TBL] [Abstract][Full Text] [Related]
39. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis.
Pelaez T; Gijón P; Bunsow E; Bouza E; Sánchez-Yebra W; Valerio M; Gama B; Cuenca-Estrella M; Mellado E
J Clin Microbiol; 2012 Jul; 50(7):2531-4. PubMed ID: 22573589
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
